Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) | NeoGenomics Laboratories

Publication date

Thu, 03/25/2021 - 12:00

Category

Year

External link

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996662/

Division